Background. The purpose of this study was to investigate the therapeutic potential of prolonged inhibition of atrial natriuretic factor (ANF) degradation in patients with severe chronic heart failure.
D iuretic therapy in congestive heart failure patients stimulates the renin-angiotensin system, sympathetic nervous system, and the release of antidiuretic hormone, all of which may compromise the desired hemodynamic and renal effects.1,2 In contrast, atrial natriuretic factor (ANF) induces natriuresis, diuresis, and vasodilatation and inhibits the neurohumoral axis.3 These latter actions are particularly useful in treating patients with sodium-and water-retaining disorders such as congestive heart failure and essential hypertension. Although short-term administration of ANF exerted beneficial effects on hemodynamic, renal, and neurohumoral parameters in patients with severe chronic heart failure,4-6 its therapeutic potential has been challenged by our observation that prolonged administration of this peptide in pharmacological doses, associated with a marked increase of plasma ANF levels, causes a shift of plasma constituents (fluid and protein) into the third space. 7 At that time, we proposed that either intermittent administration of ANF or only modest increases in plasma ANF may avoid these side effects while still exerting beneficial effects on hemodynamic, renal, and neurohumoral parameters.
The peptide ANF is degraded enzymatically by a neutral metalloendopeptidase E.C.3.4.24.11. (NEP8-10). This enzyme is located in high concentrations in renal tissue in microvilli of the brush border of the proximal tubules.8 9 Inhibition of this endopeptidase causes modest increases in plasma ANF levels (two-to threefold), along with significant diuresis and natriuresis in control subjects'0-'2 and patients with mild chronic heart failure.13,'4 Importantly, NEP inhibition has been found to produce greater natriuresis and diuresis than that produced by equivalent plasma levels of ANF obtained from exogenously administered ANF. 15 Despite these encouraging observations, the therapeutic efficacy of NEP inhibition in patients with severe chronic heart failure, particularly after repeated administration, remains to be determined. Therefore, the aim of the present study was to investigate 1) the efficacy of candoxatrilat, a recently developed NEP inhibitor, on renal and hemodynamic parameters, plasma ANF and pro-ANF(31-67) levels, and on neurohormones and 2) whether the effects are sustained after repeated administration.
Methods
Nine patients with chronic congestive heart failure were studied after giving written informed consent. The experimental protocol was approved by the ethical committee of the University of Freiburg. The group consisted of six men and three women (mean age, 63±2 years; range, 56-78 years) with an ejection fraction (determined by left ventricular angiography) c30% (Table 1) . Seven patients were in New York Heart Association functional class III, and two were in class IV. Five patients had cardiomyopathy caused by coronary artery disease and four patients idiopathic dilated cardiomyopathy. Patients with a history of myocardial infarction, valvular heart disease, or recent acute decompensation were excluded. Four days before the study, angiotensin converting enzyme inhibitors were discontinued and 2 days before the study, short-acting vasodilators and diuretics were stopped (Table 1) . Anticoagulants, antiarrhythmic agents, and digitalis were continued throughout the study. At 8 AM on the day of the study, a 7F Swan-Ganz thermodilution catheter was placed percutaneously via the basilic vein and advanced into the pulmonary artery under fluoroscopy. A urinary catheter was placed for urine sampling. Thereafter, a light breakfast was provided (one cup of tea and one sandwich). Additional light meals were provided immediately after hemodynamic measurements at 1 PM and 5 PM (Table 2) . Urine produced in the initial 60-minute equilibration period was discarded. At 9 AM, a 4-hour control urine collection was started. Hemodynamic stability (<10% variation) was ensured by two consecutive measurements performed at 30-minute intervals beginning at 11 AM. Urine volume was measured using graduated cylinders. Urine potassium and sodium excretion (millequivalents per liter) were determined by flame photometry and osmolality by freezing-point depression. Urine volume was expressed as urinary flow rate (milliliters per minute). The glomerular filtration rate (GFR) was calculated as endogenous creatinine clearance. Osmolar clearance and free water clearance were determined for each collection period and expressed as milliliters per minute. Free water clearance was calculated as the difference between urinary volume and clearance of osmoles per minute. Sodium and potassium excretion rates were calculated using the standard formula. Plasma a-hANF and pro-hANF(31-67) levels, plasma catecholamines, plasma and urine c-GMP, plasma renin activity, aldosterone and arginine vasopressine (AVP) levels, and the urinary excretion rate of the stable prostacyclin metabolite 6-keto-PGF-la were determined as described previously.7'18'19 Plasma vasopressin levels of age-matched normal individuals averaged 0.47±0.1 pg/ml. The excretion rate of the stable prostacyclin (PGI2) metabolite 6-keto-PGF-la was analyzed to determine whether the concomitant inhibition of bradykinin breakdown, and therefore enhanced renal PGI2 production, contributes to natriuresis.
Statistical Analysis
Values are given as mean+SEM. Intraindividual comparisons within the 24-hour protocol (n =7 patients) were evaluated by ANOVA. The ANOVA for hormonal and renal data were performed after logarithmic transformation, but absolute values are given in the results. When the F test indicated significant differences, individual comparisons were made by the Student-Newman-Keuls test. Single comparisons were made by paired t test. A value of p<0.05 was considered significant.
Results
Atriopeptidase Inhibition: Initial Hemodynamic, Hormonal, and Renal Response (n=9)
Atriopeptidase inhibition by candoxatrilat caused a significant increase in plasma ANF with a peak enhancement (2.5-fold) 2 hours after the first dose (from 235±+59 to 591±148 pg/ml). Plasma cGMP did not change significantly (baseline, 3 .57±0.52 pmol/ml).
Plasma pro-hANF(31-67) levels declined from 3,151±599 to 2,103±461 pg/ml 4 hours after candoxatrilat dose (p<0.05).
The increase in plasma ANF concentrations was associated with a reduction in plasma norepinephrine (from 533±131 to 332±86 pg/ml), epinephrine (from 115±24 to 62±15 pg/ml), aldosterone levels (from 187±51 to 65±10 pg/ml), plasma renin activity (from 4.01 ± 1.7 to 1.91±0.7 ng/ml/hr), and plasma vasopressin (from 2.70±0.7 to 1.51±0. 43 hours after candoxatrilat coincident with peak plasma ANF levels. Heart rate, total peripheral resistance, and arterial pressure did not change significantly with candoxatrilat.
Renal baseline status was on average abnormal compared with healthy controls,12 consistent with severe heart failure. Baseline values were: sodium excretion, 58±23 ,uEq/min; fractional sodium excretion, 0.29±0.34%; potassium excretion, 57±10 ,uEq/min; fractional potassium excretion, 14.4±2%; volume excretion, 0.93±0.19 ml/min; GFR, 79+11 ml/min; free water clearance, -0.59±0.17 ml/min; and osmolar clearance, 1.49±0.28 mosm/min. After the first candoxatrilat dose, potassium excretion, fractional potassium excretion, GFR, and free water clearance did not change significantly. Volume excretion tended to increase, but the response was heterogeneous, on average, minimal, and not significant. Only patient 5 (see Table  1 ), with the lowest baseline ANF levels and a CI >2.5 I/min/m2, responded to candoxatrilat with a good diuresis (from 0.73 to maximally 6.33 ml/min). In contrast, patients 2, 3, and 6, with the highest plasma a-ANF levels (>300 pg/ml) and CI <1.7 1/min/m2 did not respond at all. To determine which hemodynamic or neurohumoral parameter most accurately predicts diuretic responders, linear regression analysis was performed. The maximal diuretic response within the first 4 hours after candoxatrilat dose correlated best with basal CI (r=0.78, p=0.012). No significant correlation was observed with basal renin activity (r= -0.61, p=0.73), basal plasma norepinephrine levels (r= -0.23), and PCP (r=0.002).
Atriopeptidase inhibition caused a significant enhancement of sodium and fractional sodium excretion and an increase in osmolar clearance with a maximum 2 hours after the first candoxatrilat dose (to 234±+80
,tEq/min, to 1.23±0.45%, and to 2.77±0.42 mosm/min, respectively). There was also a close correlation between baseline CI and the maximal natriuretic effect within 4 hours after the first candoxatrilat dose (r=0.77, p=0.011). Urinary cGMP excretion rate increased about fivefold (from 1,318±7130 to 7,080±+1,281 pmol/ min, p<0.05) 2 hours after the first candoxatrilat dose coincident with peak plasma ANF levels. The excretion rate of ANF immunoreactivity remained unchanged (266±108 pg/min). The inhibition of ANF degradation caused a significant 3.3-fold increase (p=0.01) in the excretion rate of 6-keto-PGF-1, (see Figure 1) , which suggests that coincident inhibition of bradykinin breakdown and therefore enhanced prostaglandin formation contributes to the observed increase in sodium excretion.
Atriopeptidase Inhibition: Effects of Repeated Doses (n =7)
Figures 2-6 summarize the renal, hormonal, and hemodynamic effects of repeated doses of candoxatrilat during the entire 24-hour protocol. The inhibition of ANF degradation resulted in constantly elevated plasma ANF levels (Figure 2,p<0.05 ). The endogenous ANF secretion (assessed by the determination of the pro-hANF cleavage peptide(31-67) remained suppressed throughout the entire protocol (Figure 2 ). The increase in CI was only transient. The second and third administration of candoxatrilat did not elicit significant increases in CI (Figure 3 ). Central filling pressures remained significantly reduced throughout the protocol period. Heart rate, total peripheral resistance, and arterial pressure did not change significantly. Plasma norepinephrine and epinephrine levels remained suppressed (p<0.05), and there was no evidence of activation of the renin-angiotensin-aldosterone system and plasma vasopressin (Figure 4) whether this syncope was due to a direct parasympathomimetic action of ANF211 or a consequence of the indwelling Swan-Ganz catheter. Another patient (patient 3) was withdrawn during the study protocol and was put on high-dose furosemide because of left heart decompensation. This patient had the highest PCP, CI < 1.6 1/minlm2, the highest pro-ANF(31-67) levels (6,531 pg/ml), and plasma renin activity (16 ng/ml/hr). Both patients had uneventful recoveries. Discussion The present study was undertaken to study the therapeutic potential of inhibiting ANF degradation in patients with severe chronic heart failure. Inhibition of ANF metabolism enhances the responses to exogenous ANF21t22 and leads to significant hemodynamic unloading,13 to inhibition of the neurohumoral axis," and to a striking diuresis and natriuresis in dogs with experimental heart failure'5 and patients with mild heart failure.'344 Moreover, the renal effects in response to NEP inhibition appear to be superior to exogenously administered ANF,15 suggesting different or additional diuretic mechanisms.23 Because potassium balance is in general unaffected,'0-14 this therapeutic principle of NEP inhibition combines several features, which make it particularly useful as a diuretic agent in patients with chronic heart failure.
Changes in Plasma ANF and Pro-ANF Candoxatrilat is a selective inhibitor of the metalloendopeptidase E.C.3.4.24.11.,24 an enzyme that has a widespread distribution on membranes in many tissues and organs.25 Although the kidney has been proposed to be a major site of ANF metabolism,26 recent experimental data revealed that the renal NEP plays a relatively minor role in the clearance of ANF from the plasma.27 Indeed, the liver, lung,28 vascular endothelium,29 neutrophils,30 and the so-called clearance receptor3' have been identified as important participants in the clearance of ANF. NEP inhibition by candoxatrilat in the present study caused a significant increase in plasma ANF concentrations, with a peak enhancement 2 hours after the first dose. The dose of candoxatrilat (150 mg t.i.d.) was sufficient to cause persistently elevated plasma ANF levels for a 24-hour period. Time course and degree of ANF enhancement are consistent with reports from NEP inhibition in animals,'5 control subjects,'0-12 and patients with mild congestive heart failure.'3'4 In contrast to the sustained elevation of plasma ANF, the N-terminal cleavage peptide pro-ANF(31-67) levels declined within 2 hours after the first candoxatrilat dose and remained significantly suppressed during the entire protocol. Recent experimental data demonstrated that in response to atrial stretch, pro-ANF(31-67) and the C-terminus appear to be secreted simultaneously.32 This indicates that pro-ANF(31-67) can be used as a marker for the endogenous ANF secretion during exogenous administration of the biological active peptide. Furthermore, the demonstration of a stretchdependent release suggests that the suppression of to i f . pro-ANF(31-67) levels is secondary to the reduction of left atrial pressure and RAP.
Inhibition of Neurohumoral Axis
An important observation of the present study is that the two-to threefold increase in plasma ANF concentrations was associated with a sustained reduction in circulating plasma norepinephrine and epinephrine levels. This observation of an inhibitory action on sympathetic activity by ANF is consistent with studies performing sympathetic nerve recordings,33 catecholamine kinetics in dogs,3435 and reflex responses in human subjects.36,37 The effects on circulating catecholamines seem to be more pronounced when the increase in plasma ANF concentrations is within a physiological rather than a pharmacological range.7 This indicates that the sympathetic inhibitory action of ANF may be frequently masked with administration of pharmacological doses, e.g., due to a drop in MAP and subsequent activation of baroreceptor reflexes.7'Th Concomitantly, we observed a significant reduction in plasma renin activity and plasma aldosterone levels similar to observations in normal controls." The inhibition of aidosterone release might be explained by a reduction in plasma renin levels39 or by direct inhibition of aldosterone production in adrenal zona glomerulosa cells. 41 Interestingly, in the adrenal cortex, endopeptidase 24.11 is localized to the glomerulosa cells, where it may serve to inactivate ANF.8 Therefore, it is tempting to speculate that inhibition of the adrenal endopeptidase contributes to the observed reduction of aldosterone secretion. We also observed a transient reduction in plasma vasopressin levels. This is in line with recent reports demonstrating that ANF inhibits AVP neurons in the paraventricular nucleus4' and the posturally mediated release in humans. 42 
Hemodynamic Effects
The principal hemodynamic response to repeated NEP inhibition was characterized by a persistent reduction in PCP and RAP similar to control subjects and patients with mild heart failure'2-14 and by a brief increase in CI. These hemodynamic effects were similar to previous observations using pharmacological doses of intravenous ANF in patients with severe chronic heart failure.7 This shows that NEP inhibition, associated with only modest increases in plasma ANF concentrations, results in an effective hemodynamic unloading in patients with severe heart failure. The reduction in central filling pressures appear to be mediated by a decrease in preload rather than afterload, because systemic vascular resistance did not change.
In patients with severe chronic heart failure, prolonged infusion of ANF in pharmacological concentrations is accompanied by fluid and protein extravasation, suggesting that part of the observed preload effect might be triggered by extravasation of plasma to interstitial compartments.4,7,43 Moreover, low-dose ANF infusion, associated with a four-to fivefold increase in plasma ANF levels, increased forearm capillary filtra- 6 ). In contrast, GFR, water and potassium excretion, and free water clearance remained unchanged, and fractional potassium excretion was significantly suppressed.
Candoxatrilat is less effective in inducing natriuresis and diuresis in patients with severe heart failure when compared with normal controls'2 (also see "Results"). The close correlation between diuretic and natriuretic response and baseline CI indicates that a low cardiac output and therefore compromised renal perfusion most accurately predicts natriuretic and diuretic resistance in patients with heart failure, a phenomenon also demonstrated for loop diuretics and thiazides.48 The mode of natriuretic action induced by ANF is still debated. Proposed mechanisms include renal hemodynamic changes or a direct inhibition of sodium absorption at the proximal tubules or the inner medullary collecting duct. 49 The demonstration that the inhibition of the neutral endopeptidase causes natriuresis in the absence of changes in GFR and systemic hemodynamics suggests a renal tubular action of ANF. This assumption is supported by experimental data demonstrating an increased fractional excretion of lithium (marker for proximal tubule sodium reabsorption)l5 and an inhibition of angiotensin Il-stimulated proximal tubule sodium reabsorption50 in response to ANF degradation, inhibition, or administration. However, a drug that inhibits proximal sodium transport should stimulate the potassium secretory pathway in the distal nephron. 51 The observed unchanged potassium excretion rate in the present study (see Figure  5 ) might therefore be compatible with a more distal effect, e.g., in the inner medullary collecting duct. An additional site of action would also explain why atriopeptidase inhibitors produce a greater and more persistent natriuresis when compared with exogenously administered ANF in physiological and pharmacological concentrations.7 '15,52,53 The inhibition of ANF degradation at the proximal tubule has been reported to be linked to an increased excretion of ANF immunoreactivity.11,'3'4 This led several investigators1523 to speculate that high, intraluminal concentrations of undegraded ANF may act intraluminally or on distal ANF receptors, even when they are located on basolateral membranes of the contraluminal side. In the present study, however, we observed a dissociation between urinary ANF and sodium excretion. Whereas the sodium excretion rate increased almost sixfold, the urinary ANF did not change.
In this context, it should be stressed that NEP is known to cleave a variety of other vasoactive peptides such as bradykinin, encephalin, and substance P,9 in addition to ANF, which might contribute to the observed hemodynamic, renal, and hormonal changes induced by candoxatrilat. Bradykinin stimulates prostaglandin production together with natriuresis in the kidney,54'55 and recent experimental data demonstrate that NEP inhibition is associated with a substantial increase in the excretion rate of kinins and sodium.56 Furthermore, antibradykinin antibodies blocked, quantitatively similar to ANF antibodies, natriuresis induced by NEP inhibitor thiorphan in volume-expanded rats.57 Therefore, the observed increase in 6-keto-PGF-la excretion rate (secondary to inhibition of bradykinin breakdown) might indicate that the endogenous kiningenerating system of the kidney may also participate in the observed natriuretic responses to candoxatrilate in patients with congestive heart failure.
Summary
The present study demonstrates that repeated NEP inhibition with candoxatrilat (150 mg i.v. t.i.d) causes persistent elevation of plasma ANF levels, hemodynamic unloading associated with a reduction of endogenous ANF secretion (pro-ANF ), and supression of neurohumoral activity. However, candoxatrilat failed to elicit a significant diuresis in patients with low resting cardiac output. Nevertheless, in the presence of moderate renal effects, the inhibitory actions of candoxatrilat on the neurohumoral axis, together with hemodynamic unloading, suggests that the inhibition of ANF degradation may be a useful adjunct in moderate heart failure. This spectrum of action would be advantagous for a first-line diuretic agent early in the course of the disease rather than in patients with advanced chronic heart failure. Further studies are warranted to elucidate whether combination therapy with a vasodilator or another diuretic agent may be more effective in inducing a diuretic response in the severly ill patient population than candoxatrilat alone.
